id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15198 R62335 |
Cohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 | Nervous system malformation | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 0.70 [0.26;1.87] | -/2,674 -/4,866,362 | - | 2,674 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12856 R48495 |
Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Neural malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.33 [0.07;23.98] C excluded (control group) |
6/490 0/50 | 6 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12858 R48507 |
Thomas (Carbamazepine) (Controls unexposed, sick), 2021 | Neural malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 9.13 [0.51;162.59] C | 6/490 0/340 | 6 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9763 R34867 |
Ban (Carbamazepine) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 | Nervous system anomaly | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.39 [0.10;59.00] C excluded (control group) |
1/343 0/273 | 1 | 343 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9764 R34873 |
Ban (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 | Nervous system anomaly | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 2.05 [0.29;14.60] C | 1/343 367/257,153 | 368 | 343 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R34315 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Nervous system | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 0.40 [0.02;9.96] C | 0/685 1/833 | 1 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.12 [0.41;3.07] | 375 | 4,192 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Mixed indications) (Controls unexposed, NOS; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Mixed indications) (Controls unexposed NOS; 4: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9763, 12856